JP2005527495A - 治療化合物 - Google Patents

治療化合物 Download PDF

Info

Publication number
JP2005527495A
JP2005527495A JP2003565430A JP2003565430A JP2005527495A JP 2005527495 A JP2005527495 A JP 2005527495A JP 2003565430 A JP2003565430 A JP 2003565430A JP 2003565430 A JP2003565430 A JP 2003565430A JP 2005527495 A JP2005527495 A JP 2005527495A
Authority
JP
Japan
Prior art keywords
linker
ligand
compound
transporter
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527495A5 (cg-RX-API-DMAC10.html
Inventor
ピーター シー メルツァー
バーサ ケイ マドラス
ポール ブランデル
シャンガオ ルイ
Original Assignee
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
オーガニックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ, オーガニックス インコーポレイテッド filed Critical プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Publication of JP2005527495A publication Critical patent/JP2005527495A/ja
Publication of JP2005527495A5 publication Critical patent/JP2005527495A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2003565430A 2002-02-08 2003-02-10 治療化合物 Pending JP2005527495A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35511102P 2002-02-08 2002-02-08
US36740002P 2002-03-25 2002-03-25
PCT/US2003/004023 WO2003066004A2 (en) 2002-02-08 2003-02-10 Therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2005527495A true JP2005527495A (ja) 2005-09-15
JP2005527495A5 JP2005527495A5 (cg-RX-API-DMAC10.html) 2006-03-30

Family

ID=27737484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565430A Pending JP2005527495A (ja) 2002-02-08 2003-02-10 治療化合物

Country Status (6)

Country Link
US (2) US7439264B2 (cg-RX-API-DMAC10.html)
EP (1) EP1478356A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005527495A (cg-RX-API-DMAC10.html)
AU (1) AU2003215150A1 (cg-RX-API-DMAC10.html)
CA (1) CA2476218A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003066004A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522736A (ja) * 2007-03-29 2010-07-08 レナスキー・コンサルタンシー・リミテッド 方法、組成物、及びその使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007100775A2 (en) * 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
US8697888B2 (en) * 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531483B1 (en) 1990-08-09 2003-03-11 Research Triangle Institute Cocaine receptor binding ligands
US6241963B1 (en) 1995-10-19 2001-06-05 The Trustees Of The University Of Pennsylvania Dopamine and serotonin transporter ligands and imaging agents
US5948933A (en) 1997-07-11 1999-09-07 Organix, Inc. Tropane analogs and methods for inhibition of monoamine transport
AU1797700A (en) 1998-12-14 2000-07-03 Nuclear Receptor Research Limited Novel ligands of nuclear receptor
CA2721484A1 (en) 1999-05-12 2000-11-12 President And Fellows Of Harvard College Dopamine transporter imaging agents
US6479509B1 (en) 2000-05-22 2002-11-12 Research Triangle Institute Method of promoting smoking cessation
US6525206B1 (en) * 2000-10-17 2003-02-25 President And Fellows Of Harvard College Compounds with high monoamine transporter affinity
GB2380733A (en) 2001-10-11 2003-04-16 Bertha Kalifon Madras Non-amine tropane analogues

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6009040540, Med. Chem. Res., 1998, 8, 12−34 *
JPN6009040543, J. Med. Chem., 1995, 38, 379−388 *
JPN6009040545, J. Pharmacol. Exp. Ther., 1997, 282, 467−474 *
JPN6009040550, J. Label. Compds. Radiopharm., 1997, XXXIX, 757−772 *
JPN6009040552, Bioorg. Med. Chem. Lett., 1996, 6, 2871−2874 *
JPN6009040556, J. Med. Chem., 1998, 41, 4429−4432 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522736A (ja) * 2007-03-29 2010-07-08 レナスキー・コンサルタンシー・リミテッド 方法、組成物、及びその使用

Also Published As

Publication number Publication date
US7439264B2 (en) 2008-10-21
US20030232827A1 (en) 2003-12-18
WO2003066004A2 (en) 2003-08-14
EP1478356A2 (en) 2004-11-24
EP1478356A4 (en) 2005-03-16
AU2003215150A8 (en) 2003-09-02
CA2476218A1 (en) 2003-08-14
AU2003215150A1 (en) 2003-09-02
US20090048284A1 (en) 2009-02-19
WO2003066004A3 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
US20090048284A1 (en) Therapeutic compounds
JP3553083B2 (ja) 末梢性活性抗痛覚過敏オピエート
ES2329739T3 (es) Analogos de cocaina.
HRP20110946A2 (hr) Enantiomeri spirooksindolskih spojeva i njihova upotreba kao terapijska sredstva
US8987293B2 (en) Morphinans useful as analgesics
JP3708957B2 (ja) (−)−エゼロリン、(−)−n1−ノルエゼロリンおよび(−)−n1−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩:特異的アセチルコリンエステラーゼ阻害薬としての使用
CN102762201A (zh) 注意力缺陷/多动症的治疗方法
JP2010511717A (ja) プロドラッグおよびその作成ならびに使用方法
CN102186883A (zh) Nmda受体调节剂和其用途
AU2005225458A1 (en) Neural tourniquet
CN101248069A (zh) 雄激素受体调节剂及用其治疗疾病的方法
ES2269467T3 (es) Tratamiento de transtornos afectivos por la accion combinada de un agonista del receptor nicotinico y una sustancia monoaminergenica.
ES2250345T3 (es) Derivados sustituidos de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico.
US6380175B1 (en) Method for enhancement of delivery of THC by the administration of its prodrugs via the nasal route
US9463187B2 (en) Methylphenidate derivatives and uses of them
JP2019531260A (ja) テトラヒドロイソキノリンカッパーオピオイドアンタゴニスト
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
WO1996031470A1 (en) Novel heterocyclic compounds
ES2432216T3 (es) Derivados de 2-(1,2-Bencisoxazol-3-il)bencilaminas
JP2007506784A (ja) 双極性障害およびその他の認知障害の治療における、ケレリトリン、その類似体およびそれらの使用
KR100196263B1 (ko) 아로일 우레아 유도체
BRPI0506814A (pt) composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, processo para preparar uma composição farmacêutica, e, métodos para tratar um indivìduo sofrendo de um distúrbios afetivo, para tratar um indivìduo sofrendo de um distúrbio urinário e para tratar um indivìduo sofrendo de um distúrbio de alimentação
JP2001504850A (ja) 不安を伴う重抑鬱性障害を治療するためのnk−1受容体拮抗薬の使用
JP4071012B2 (ja) セロトニンの伝達抑制物質
WO2025199359A1 (en) Methods of modulating cdk7 and flt3 using fused bicyclic compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100412